Old Web
English
Sign In
Acemap
>
authorDetail
>
Florian Wittlinger
Florian Wittlinger
University of Tübingen
Epidermal growth factor receptor
Mutant
Cancer research
Chemistry
Osimertinib
4
Papers
10
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer.
2021
Expert Opinion on Drug Discovery
Florian Wittlinger
Stefan Laufer
Show All
Source
Cite
Save
Citations (2)
Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.
2021
Journal of Medicinal Chemistry
Florian Wittlinger
David E. Heppner
Ciric To
Marcel Günther
Bo Hee Shin
Jaimin K. Rana
Anna M Schmoker
Tyler S. Beyett
Lena M. Berger
Benedict-Tilman Berger
Nicolas Bauer
James D. Vasta
Cesear Corona
Matthew B. Robers
Stefan Knapp
Pasi A. Jänne
Michael J. Eck
Stefan Laufer
Show All
Source
Cite
Save
Citations (0)
Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors.
2020
Journal of Medicinal Chemistry
David E. Heppner
Marcel Günther
Florian Wittlinger
Stefan Laufer
Michael J. Eck
Show All
Source
Cite
Save
Citations (8)
Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor
2020
ChemRxiv
Florian Wittlinger
David E. Heppner
Ciric To
Marcel Guenther
Bo Hee Shin
Jaimin K. Rana
Anna M. Schmoker
Tyler S. Beyett
Pasi A. Jänne
Michael J. Eck
Stefan Laufer
Show All
Source
Cite
Save
Citations (0)
1